Viela Bio (NYSE:VIE) announced its quarterly earnings results on Sunday. The company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.07, MarketWatch Earnings reports.
Shares of VIE opened at $33.92 on Monday. The company’s fifty day moving average is $31.79 and its two-hundred day moving average is $39.07. Viela Bio has a 1 year low of $23.69 and a 1 year high of $70.66.
Several research analysts have recently weighed in on VIE shares. HC Wainwright dropped their price target on shares of Viela Bio from $75.00 to $52.00 and set a “buy” rating on the stock in a research note on Thursday. Stifel Nicolaus reiterated a “hold” rating and set a $48.00 price target on shares of Viela Bio in a report on Thursday, August 13th. Wedbush lowered their price objective on shares of Viela Bio from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Wednesday, November 11th. Finally, Zacks Investment Research raised shares of Viela Bio from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research report on Tuesday, October 20th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Viela Bio has a consensus rating of “Buy” and a consensus target price of $55.25.
Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases.
Featured Article: CD Ladder
Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with MarketBeat.com's FREE daily email newsletter.